grepcent public filings, reorganized for comparison

AFREZZA — FDA application BLA022472

Application BLA022472 · type BLA · FDA status: approved · original approval 2014-06-27

Listed sponsor: MANNKIND · MNKD company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001AFREZZAINSULIN RECOMBINANT HUMANPOWDERINHALATION4 UNITS/INHPrescriptionnot listednot listed
002AFREZZAINSULIN RECOMBINANT HUMANPOWDERINHALATION8 UNITS/INHPrescriptionnot listednot listed
003AFREZZAINSULIN RECOMBINANT HUMANPOWDERINHALATION12 UNITS/INHPrescriptionnot listednot listed

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

Patent/exclusivity listings: not applicable — the FDA Orange Book covers NDA and ANDA small-molecule applications, not BLA biologics.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: No published peer-cluster link for this sponsor.

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.